GLP1R Knockout BEAS-2B Cell Line

The choice depends on whether you are studying GLP1R's role as the GLP-1 receptor or modeling its emerging functions in respiratory biology and inflammation. The Knockout line is the standard tool for asking whether GLP1R is required for GLP-1-induced signaling — GLP1R is a Gs-coupled class B GPCR activated by GLP-1 (and GLP-1-mimetic drugs), driving cAMP-PKA signaling for insulin secretion (canonical β-cell function) and weight loss/satiety effects (CNS); GLP1R has emerging non-pancreatic functions in lung, kidney, and immune cells. Overexpression is useful for studying GLP1R in heterologous expression contexts. For respiratory biology research, the EDITGENE GLP1R Knockout in BEAS-2B is highly relevant — BEAS-2B is a normal human bronchial epithelial cell line, and GLP1R has emerged as expressed in respiratory epithelium with implications for asthma and COPD biology. Rescue with wild-type or signaling-deficient GLP1R enables structure-function studies. The knockout is a critical specificity control for GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy, FDA-approved for T2D and obesity), tirzepatide (Mounjaro/Zepbound, dual GIP/GLP-1 agonist), liraglutide, exenatide — and emerging GLP1R-targeted respiratory disease therapeutics.

Primary applications: • GLP-1-induced signaling: cAMP elevation, PKA activation following semaglutide, tirzepatide, liraglutide, or exenatide stimulation in GLP1R-null cells. • Respiratory GLP1R biology: in bronchial epithelial context, characterization of GLP1R's emerging roles in airway inflammation and asthma/COPD biology. • Critical drug specificity: critical genetic control for semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound, dual GIP/GLP-1), and emerging GLP-1-targeted obesity/diabetes drug development. • Biased agonism studies: G-protein versus β-arrestin signaling bias analysis with different GLP-1R ligands. EDITGENE recommends this BEAS-2B-based model for researchers investigating respiratory GLP1R biology and emerging non-pancreatic GLP1R functions.

Yes. GLP1R rescue experiments are well-established for GLP-1 pharmacology research: • Construct design: use a codon-modified GLP1R sequence with a small intracellular C-terminal tag (FLAG, HA). GLP1R is a class B GPCR with large extracellular ligand-binding domain and seven-transmembrane region — preserve all elements. • Signaling-deficient rescue: DRY motif or specific intracellular loop mutations disrupt Gs-coupling. • Biased signaling studies: specific mutations can generate G-protein-biased or β-arrestin-biased GLP1R variants for biased agonism research. • Functional readout: rescue should restore semaglutide/tirzepatide-induced cAMP elevation and PKA-dependent downstream signaling. BEAS-2B-specific considerations: • BEAS-2B is a SV40-immortalized normal human bronchial epithelial cell line — widely used for respiratory epithelial biology, environmental toxicology, and airway disease research. • Lentiviral transduction is supported but may require optimization compared to standard transformed cell lines. • BEAS-2B's normal bronchial epithelial origin makes it relevant for non-cancer respiratory studies.